About Aragen Life Sciences Ltd.
Incorporated in December 2000, Aragen Life Sciences Limited is a fully integrated contract research, development and manufacturing organization (CRDMO) serving global pharmaceutical, biotechnology and other life sciences companies. The Company offers comprehensive solutions across the drug development lifecycle through its CRO and CDMO businesses, covering both small molecules and biologics. Its services include drug discovery and pre-clinical research, advanced chemistry and biology solutions, process R&D, API and intermediate development, formulation development, GMP manufacturing, analytical testing and integrated gene-to-GMP biologics solutions.
The Company serves a diversified global customer base comprising Big Pharma, large pharmaceutical companies, biotechnology firms and mid-sized pharmaceutical companies across pharmaceuticals, biotechnology, animal health, agrochemicals and specialty chemicals. In Fiscal 2026, it served 591 customers globally, including 16 of the Top 20 Big Pharma companies, with presence across the United States, Europe, Japan, India and other APAC markets. Its integrated US-India delivery model combines advanced scientific capabilities in the United States with large-scale research and manufacturing infrastructure in India.
The Company operates capabilities across peptides, oligonucleotides, nucleic acid chemistry, PROTACs, lipids, bio-conjugation, DMPK, pharmacology, cell and protein sciences and molecular biology, along with small molecule and biologics development and manufacturing. As of March 31, 2026, it had an installed small molecule CDMO capacity of 364.12 KL, clinical-scale formulation capacity of 1 million doses per annum, and 2.50 KL of GMP biologics manufacturing capacity. During Fiscal 2026, its chemistry laboratories synthesized over 60,000 novel compounds and screened over 50,000 compounds across biology programmes.
As of March 31, 2026, the Company has a strong scientific workforce, with 4,362 permanent employees, including 3,412 scientific personnel and 479 PhD holders.
Competitive Strengths
- Demonstrated track record of consistent and profitable growth.
- Professional management and highly qualified scientific workforce.
- Leading CRO platform supported by advanced capabilities and strong scientific talent.
- Scalable small molecule and biologics CDMO capabilities with an integrated US-India delivery model.
- Largest Indian CRDMO platform offering comprehensive solutions across the drug development lifecycle.
- Diversified revenue base with deep and long-standing relationships with global pharmaceutical customers.
- Strategically located advanced infrastructure across India and the United States with a strong regulatory track record.
(Updated on Aug 27, 2026)
